Colin D. Funk

Colin Funk, Ph.D. serves as the Science Lead at Clairvoyant Therapeutics Inc. since October 2020 and as the Scientific Lead at Novateur Ventures Inc. since June 2019, focusing on COVID-19 therapeutics, vaccines, and cannabinoid biosynthesis. In academia, Colin Funk holds positions as an Adjunct Professor and Tier 1 Canada Research Chair in Molecular, Cellular and Physiological Medicine at Queen's University, leading interdisciplinary research in cardiovascular, metabolic, and inflammation studies since July 2004. Previous roles include Visiting Professor at BC Cancer and Principal Investigator at STEMCELL Technologies. Colin Funk's educational background includes a PhD in Experimental Medicine from McGill University, a postdoctoral degree in Physiological Chemistry from Karolinska Institutet, and a Bachelor of Science in Biochemistry from Queen's University.